Toll free: 1-855 542-5672 (1-855-KICK-MSA)
en English
af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sudanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu
DONATE

MSA
RESEARCH

CURRENT TRIALS

BASIC SCIENCE RESEARCH

NEW PROMISING MSA DISEASE MODIFYING DRUG TRIAL

Verdiperstat, a new first-in-class, brain-penetrant, irreversible myeloperoxidase (MPO) inhibitor that is being developed for the treatment of multiple system atrophy (MSA).

  • Has the potential to be developed in a number of disease indications associated with oxidative stress, inflammation, and neurodegeneration.
  • Potential to be a first-in-class and best-in-class agent.
  • Licensed from AstraZeneca in September 2018, where it was known as AZD3241.

MSA is considered to be a rare disease, affecting approximately 15,000 to 50,000 Americans. Some symptoms can be treated with medications but currently, there is no cure. Biohaven hopes to change that landscape with Verdiperstat, the first drug that may slow multiple system atrophy. For the latest press release on the phase 3 drug trial from Biohaven, visit here. 

NEW NOVEL DRUG RESEARCH – PBT434 (Alterity pharmaceuticals)

“Alterity’s compound, PBT434 was granted orphan designation in USA & EU for Multiple System Atrophy;” Press Release from Alterity: https://alteritytherapeutics.com/…/european-commission-app…/

“Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases”  Click here for the press release. 

NEW PRE-CLINICAL MSA RELEVANT RESEARCH SUCCESS

CONGRATS TO OUR FRIEND DAVID MARMION ON HIS NEW MSA RESEARCH!

“These results suggest that T cell priming and infiltration into the CNS are key mechanisms of disease pathogenesis in MSA, and therapeutics targeting T cells may be disease modifying.” Click here to read about his study.

“Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease” Click to read the study here.

Photo Below: David Marmion helps #KICKMSA

“Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance” (2020); Click here to read the open access research study about a new compound

BRAIN
DONATIONS

NOTE: Due to the current global Covid-19 Pandemic, some brain banks are not back to full capacity in their operations. After completing the form below, we will discuss current options given this pandemic.

About Brain Donations:

Brain donations could help researchers find the cause(s), more treatments and a cure for MSA. The examination of brain tissue is vital in this research process. A brain donation involves a simple procedure and it does not hinder the funeral or any burial plans. In some cases, the cost of brain procurement (when a technician removes it and sends it to a brain bank) can be offset by a grant from an institution or charity.

For many, a brain donation is the ultimate gift for generations to come – because MSA brain research could help bring about more treatments, more ways to help diagnose MSA and eventually, a cure!

If you are a patient and are considering a brain donation, please contact us, using the information below. There are several institutions in US, Canada and other countries as well, that are currently doing MSA related brain research and desperately need brain donations. There is a place on the form to indicate the choice of brain bank, if applicable.

For families in the USA or Canada, we will help you facilitate a brain donation. Because Defeat MSA Alliance is an IRS approved public charity, we do not collaborate with nor support any 3rd party profit-driven brain procurement organizations or companies. 

Defeat MSA Alliance does not require a fee nor do we request any money from you, in order to help you donate a brain to any brain bank.

Regarding why we ask for your power of attorney: brain banks generally require the contact information for the donor’s power of attorney and the current physician, in addition to the donor information.

All information submitted on this form is strictly confidential. No specifics will be shared with the brain bank until we make our first contact with you as the potential donor or your personal representative.

If you have been diagnosed with MSA, are interested in donating your brain and need help facilitating this ultimate and lasting gift, please call us toll free: 1 855 542-5672 (1 855 KICK-MSA) or email us: braindonation@defeatmsa.org

If calling, please leave your name, number, reason for your call and best time to return your call. Thank You!

  • Contact Information

  • Power of Attorney Information

  • Physician Information

GET INVOLVED

RESEARCHER BLOG

Browse The Latest
Dr. Amanda Woerman

Dr. Amanda Woerman

Dr. Wouter Peelaerts

Dr. Wouter Peelaerts

Member, Science and Medical Advisory Board

*NEW* IMPORTANT UPDATE – INFORMATION FROM BIOHAVEN

Jun 11, 2021 | | 0 Comments

JUNE 1, 2021 DEFEAT MSA ALLIANCE RESEARCH PROGRAM ADVISORS: IMPORTANT QUESTIONS & INFORMATION FROM BIOHAVEN   Can I still join the trial? Answer:  Enrollment for the phase 3 study closed in July of 2020. When are we expected to know the results of the Phase 3...

THE EXPERTS

A SPECIAL THANKS TO OUR MSA RESEARCHERS & HEALTH PROFESSIONALS AROUND THE WORLD!

Dr. Patrik Brundin

Van Andel Research Institute, Grand Rapids, Michigan, USA

Dr. Edwin George

Wayne State University, Detroit, Michigan, USA

Dr. Pravin Khemani

Swedish Neuroscience Institute, Seattle, Washington, USA

Dr. Janice Holton

University College London, London, United Kingdom

Dr. Horatio Kaufmann

Dysautonomia Center, New York University, New York, New York, USA

Dr. Wolfgang Singer

Mayo Clinic, Rochester, Minnesota, USA

Dr. Eduardo Benarroch

Mayo Clinic, Rochester, Minnesota, USA

Dr. Shilpa Chitnis

University of Texas Southwestern Medical Center, Dallas, Texas, USA

Dr. Walter J. Koroshetz

National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health, Bethesda, Maryland, USA

Dr. John Q. Trojanowski

University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA

Dr. Paola Sandroni

Mayo Clinic Rochester, Minnesota

Dr. David Robertson

Vanderbilt Autonmic Dysfunction Center, Nashville, Tennessee, USA

Dr. Philip Low

Mayo Clinic, Rochester, Minnesota, USA

Dr. Praveen Dayalu

University of Michigan, Ann Arbor, Michigan, USA

Professor Gregor Wenning

Medical University, Innsbruck, Austria

Dr. Vik Khurana

Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts, USA

Professor Eliezer Masliah

University of California, San Diego, California, USA

Dr. Matt Huentelman

T-Gen, Phoenix, Arizona, USA

Professor Glenda Halliday

Sydney Medical School, University of Sydney, Sydney, Australia

Dr. Aaron Ellenbogen

Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, USA

Professor Werner Poewe

Innsbruck Medical University, Innsbruck, Austria

Dr. Un J. Kang

Irving Medical Center, Columbia University, New York, New York, USA

Dr. Charbel Moussa

Georgetown University, Washington, DC

Dr. Thomas Chelimsky

Medical College of Wisconsin, Wauwatosa, Wisconsin, USA

Dr. Ryan Walsh

Barrow Neurological Institute, Phoenix, Arizona, USA

Dr. Chuck Ide

Weestern Michigan University, Kalamazoo, Michigan, USA

Dr. Naill Quinn

University College London, London, United Kingdom

Dr. Roy Freeman

Beth Israel Deaconess, Boston, Massachusetts, USA

Dr. Michael Janitz

University of New South Wales, Sydney, Australia

Dr. Jeffrey Cummings

Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, Nevada, USA

Dr. Joseph Jankovic

Baylor College of Medicine Medical Center, Houston, Texas, USA

Dr. Anthony Lang

Toronto Western Hospital Research Institute, Toronto, Canada

Dr. Jeffrey Kordower

Rush University, Chicago, Illinois, USA

Dr. Sid Gilman

Hope Clinic Ypsilanti, Michigan, USA

Dr. Glenn Cook

Director, Walter Reed National Military Medical Center, Clinical Neurocardiology Section, NINDS, NIH

Dr. Peter LeWitt

Henry Ford Health System, Detroit, Michigan, USA

Dr. Steven Vernino

University of Texas, Southwestern, Dallas, Texas, USA

Professor Florian Krismer

Medical University, Innsbruck, Austria

Dr. Wassilios Meissner

University Hospital Bordeaux, Bordeaux, France

Dr. Jeremy Schmahmann

Massachusetts General Hospital, Boston, Massachusetts, USA

Dr. Ronald Melki

Paris-Saclay Institute of Neuroscience, Saint-Aubin, France

Professor Shoji Tsuji

Medical Genome Center, University of Tokyo Hospital, Tokyo, Japan

Dr. Michael Schlossmacher

Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Professor Gal Bitan

University of California - Los Angeles, Los Angeles, California, USA

Dr. Wendy R. Galpern

National Institute of Neurological Disorders and Stroke at the National Institutes of Health in Bethesda, Maryland, USA

Dr. Virginia Man-Yee Lee

University of Pennsylvania, Philadelphia, Pennsylvania, USA

DISCLAIMER

Any of these online pages published by Defeat MSA Alliance are for informational and support purposes only. The information presented in them should not be used for suggesting any diagnosis or understood as recommending any medicines, tests or treatments. Every visitor should consult with his/her doctor or other health care provider for any medical condition.

Furthermore, Defeat MSA Alliance has used all reasonable care to protect your privacy, ensure confidentiality and maintain a safe and secure online presence. For questions about the website or information contained therein, contact: info@defeatmsa.org

LOOKING FOR OTHER WAYS TO GET INVOLVED?

LEARN MORE

JOIN THE MOVEMENT TO #DEFEATMSA

SUBSCRIBE TO OUR NEWSLETTER

 

Follow us on social media

Follow us on Twitter

Follow us on Facebook

Follow us on Instagram

Follow us on YouTube

Follow us on LinkedIn

 

Follow us on social media

Follow us on Twitter

Follow us on Facebook

Follow us on Instagram

Follow us on YouTube

Follow us on LinkedIn

About Us

Mission & Story
Board of Directors*
Individual Legacy Grants
Financials
Ethics Statement
Other Conduct Policies

Blogs & Downloadables

Overview MSA Treatments (EN)
Overview MSA Treatments (SP)
MSA Virtual Conference Flyer
Virtual Conference Booklet
MSA Awareness Card
Medical Resources
Researcher & Mission Blogs
MSA Patient Pamphlet
Defeat MSA Alliance Brochure
MSA Patient Wallet Card
Download Zoom MSA Backgrounds

 

Supporters

Experts of MSA
Research & Medical Advisors
Individual Supporters
Friends & Allies

Get Involved

Donate To Us
Brain Donations
Loaner Closet Program
Memorial Envelopes
Bequeaths and Wills Language
Giving Programs
Volunteer


Copyright 2021 | Defeat MSA Alliance - 501(c)(3)

 Privacy Policy

CREATEDBY | RIOSMEDIA

Copy link
CopyCopied
Powered by Social Snap